Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. The viral activation transfusion study: A randomized controlled trial

JAMA

Volumn 285, Issue 12, 2001, Pages 1592-1601

  Collier, Ann C ^a   Kalish, Leslie A ^b   Busch, Michael P ^c,d   Gernsheimer, Terry ^a,e   Assmann, Susan F ^b   Lane, Thomas A ^f   Asmuth, David M ^g   Lederman, Michael M ^h   Murphy, Edward L ^d   Kumar, Princy ⁱ   Kelley, Meera ^j   Flanigan, Timothy P ^k   McMahon, Deborah K ^l   Sacks, Henry S ^m   Kennedy, Melanie S ⁿ   Holland, Paul V ^o  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c Blood Centers of the Pacific   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e PUGET SOUND BLOOD CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g University of Texas Medical Branch School of Medicine   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k BROWN UNIVERSITY   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^m Ichan School of Medicine   (United States)

ⁿ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^o Sacramento Medical Foundation Blood Centers   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALIC INCLUSION BODY DISEASE; DEATH; DOUBLE BLIND PROCEDURE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LEUKOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REACTIVATION;

EID: 0035962095     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.12.1592     Document Type: Article

References (83)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland
4. Natural history of HIV infection in the era of combination antiretroviral therapy
5. Epidemiology of anemia in human immunodeficiency virus (HIV)infected persons
6. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe
7. Anemia and survival in HIV infection
8. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome
9. Pathogenesis and pathophysiology of anemia in HIV infection
10. Hematologic abnormalities among HIV-infected patients
11. Human immunodeficiency virus infection, anemia, and survival
12. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy
13. Recombinant human erythropoietin treatment
14. Transfusion practices in human immunodeficiency virus-infected patients
15. Transfusion of blood components to persons infected with human immunodeficiency virus type 1
16. Early transfusion and length of survival in acquired immune deficiency syndrome
17. Immune response to chronic RBC transfusion
18. Red cell alloimmunization in multitransfused HLA-typed patients
19. Transfusion-associated cancer recurrence and postoperative infection
20. Allogeneic blood transfusion-induced enhancement of tumor growth
21. Immunologic effects of blood transfusion upon renal transplantation, tumor operations, and bacterial infections
22. Biologic effects of leukocytes present in transfused cellular blood products
23. Effect of blood transfusions on subsequent kidney transplants
24. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients
25. Effect of perioperative blood transfusion on recurrence of Crohn's disease
26. Multiple blood transfusions reduce the recurrence rate of Crohn's disease
27. Treatment of recurrent spontaneous abortion by immunization with paternal lymphocytes
28. Randomised comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery
29. Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery
30. Does blood transfusion increase the risk of infection after hip fracture?
31. Multicenter randomized controlled trials in transfusion medicine
32. The effect of unmodified or prestorage white cell-reduced allogeneic red cell transfusions on the immune responsiveness in orthopedic surgery patients
33. Blood transfusion and immunomodulation
34. Mononuclear cell microchimerism and the immunomodulatory effect of transfusion
35. Immunomodulation caused by blood transfusion
36. Transfusion of the HIV-seropositive patients
37. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions
38. Transfusion-associated immunomodulation and universal white cell reduction
39. Leukocyte reduction of blood components
40. BPAC recommends universal leukoreduction
41. Safety of the blood supply in the United States
42. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection
43. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors
44. Pathogenesis of cytomegalovirus infection, I
45. Transmission and activation of cytomegalovirus with blood transfusion
46. The viral activation transfusion study (VATS)
47. Human immunodeficiency virus type 1 activation after blood transfusion
48. Impact of transfusion on viral load in human immunodeficiency virus infection
49. Problems and pitfalls in the evaluation of anticancer drugs
50. The randomization and stratification of patients to clinical trials
51. Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons
52. Lymphocyte subset analysis on frozen whole blood
53. Quantitation of white cell subpopulations by polymerase chain reaction using frozen whole-blood samples
54. Report of the NIH panel to define principles of therapy of HIV infection
55. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma
56. Detection of cytomegalovirus in plasma and cerebrospinal fluid specimens from human immunodeficiency virus-infected patients by the AMPLICOR CMV test
57. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients
58. 'Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses
59. Quantitation of residual white cells in filtered blood components by polymerase chain reaction amplification of HLA DQ-A DNA
60. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
61. Alloimmunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women
62. Guidelines on the clinical use of leucocyte-depleted blood components
63. Danish recommendations for the transfusion of leukocyte-depleted blood components
64. Lymphocyte response to blood transfusion in man
65. Assessment of donor T-cell function in cellular blood components by the CD69 induction assay
66. Complement activation during storage of whole blood, red cells, plasma, and buffy coat
67. Cytokines in stored RBC concentrates
68. Cytokine generation in whole blood, leukocyte-depleted and temporarily warmed RBC concentrates
69. White cell apoptosis in packed red cells
70. Supernatant from stored red cells activates neutrophils
71. Effect of storage on lymphocyte surface markers in whole blood units
72. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
73. Benefits of leukocyte-reduced blood transfusion in surgical patients
74. Blood transfusion and total joint replacement surgery
75. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
76. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products
77. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes
78. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
79. Methods for the reduction of transfusion-transmitted cytomegalovirus infection
80. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time
81. Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome
82. Isolation of multiple cytomegalovirus strains from a patient with adult T cell leukemia
83. Coinfection of the immunocompromised but not the immunocompetent host by multiple human cytomegalovirus strains